Arthritis Drug Tocilizumab Improves Remission in Resistant Depression Trial
Researchers at the University of Bristol reported that tocilizumab, an arthritis medication, lifted remission rates to 54% among patients with treatment‑resistant depression, compared with 31% for placebo. The pilot trial suggests that targeting inflammation could become a new avenue for mental‑health treatment.
Rejuvenate Biomed Completes Phase 2 Recruitment for RJx-01 COPD Sarcopenia Trial
Rejuvenate Biomed announced today that it has finished enrolling participants in the randomized, double‑blind Phase 2 MINT‑COPD trial of RJx-01, its multi‑pathway candidate for COPD‑induced sarcopenia. The milestone moves the company toward topline data expected by year‑end 2026 and positions...
Meta Labs Pharmaceuticals, LLC - 725130 - 05/15/2026
The FDA issued a warning letter to Meta Labs Pharmaceuticals after a December 2025 inspection uncovered multiple violations. The agency determined that the company’s products—such as Diabetic Advantage, Yacon Root Extract, Nattokinase Max, Viral Immune Booster, Arthritis Bursitis Rheumatism, and Respiratory...
Aeroflex Industria De Aerosol Ltda. - 728186 - 05/22/2026
The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research issued a Warning Letter to Aeroflex Industria de Aerosol Ltda., a Brazilian OTC drug manufacturer, after the company failed to respond to a 704(a)(4) records request sent on...
Abivax’s Obefazimod Shows Maintenance Benefit in Phase 3 Ulcerative Colitis Trial, Shares Slip
Abivax SA announced that its oral therapy Obefazimod achieved statistically significant remission rates in the pivotal Phase 3 ABTECT maintenance trial for ulcerative colitis, enrolling 580 patients. The 25 mg and 50 mg doses both surpassed placebo, driving a sharp drop in...
Voyager Therapeutics Secures FDA IND Clearance for Alzheimer’s Gene Therapy VY1706
Voyager Therapeutics announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for VY1706, an siRNA‑based gene therapy aimed at reducing tau protein in early Alzheimer’s disease. The company will begin a multi‑site, open‑label dose‑escalation trial...
Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and In Vivo Cell Therapy
Circio and GenAssist have launched a research partnership to create circVec‑enhanced AAV vectors for low‑dose, muscle‑targeted gene therapy and in‑vivo cell therapy. The collaboration blends Circio’s circular RNA expression technology with GenAssist’s tissue‑specific, liver‑de‑targeted capsids, aiming to cut systemic dosing...
Targeted Drug Shrinks Tumors In Hard-To-Treat Cancer
A new antibody‑drug conjugate (ADC) that delivers chemotherapy directly into cancer cells showed promising activity in a Phase II trial for women with recurrent or refractory uterine cancer. About one‑quarter of participants experienced tumor shrinkage, and more than half saw...
M15 General Principles for Model-Informed Drug Development
The U.S. Food and Drug Administration has issued the final version of its M15 guidance, titled “General Principles for Model‑Informed Drug Development.” Developed under ICH, the document outlines best practices for planning, evaluating, and documenting MIDD evidence, and establishes a...
Everest Medicine Licenses Civorebrutinib to Travere Therapeutics in a ~$1.14B Deal
Everest Medicines has signed an exclusive licensing and collaboration agreement with Travere Therapeutics to develop and commercialize the BTK inhibitor civorebrutinib worldwide, excluding China and certain Asian markets. Everest will receive $112.5 million upfront and up to $1.03 billion in milestone payments,...
Genentech Receives the US FDA Priority Review for Giredestrant as an Adjuvant Treatment of ER+ Early-Stage Breast Cancer
Genentech’s oral selective estrogen receptor degrader giredestrant has received FDA priority review for use as an adjuvant therapy in estrogen‑receptor‑positive, HER2‑negative, ESR1‑mutated early‑stage breast cancer. The filing is backed by the lidERA Phase III trial, which enrolled more than 4,100 patients...
Roche Secures FDA Priority Review for Giredestrant, a New Oral Breast Cancer Therapy
Roche announced that the U.S. FDA has accepted its New Drug Application for giredestrant under priority review, targeting estrogen‑receptor‑positive, HER2‑negative breast cancer in stages I‑III. The agency aims to decide by Nov 30 2026, a timeline that could accelerate market entry for...
Biotech Takeover Target Abivax Sinks over 30% as Cancer Cases Cloud Trial Data for Bowel Disease Drug
Abivax’s shares plunged up to 32% after a Phase‑2 maintenance study of its ulcerative colitis drug obefazimod reported a 40% placebo‑adjusted remission rate but also identified several cancer cases in the higher‑dose arm. The market value fell to roughly $7.6 billion,...
ResMed Completes Noctrix Health Acquisition, Adding RLS Therapy to Sleep‑health Portfolio
ResMed announced the completion of its acquisition of Noctrix Health, expanding its clinical sleep‑health suite to include the FDA‑cleared Nidra™ Tonic Motor Activation (TOMAC) therapy for restless‑legs syndrome (RLS). The deal makes Noctrix a wholly‑owned subsidiary and positions ResMed to...
BMS Secures FDA Acceptance for Camzyos sNDA
FDA has accepted Bristol Myers Squibb’s supplemental NDA for Camzyos (mavacamten) to treat adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy, granting priority review with a PDUFA target date of September 30, 2026. The decision follows the...
Sunshine Biopharma Shares Surge 66% After Reverse Split and Canadian Approval of Generic Rivaroxaban
Sunshine Biopharma Inc. (SBFM) saw its shares climb 66% in pre‑market trading on June 2, 2026, after completing a 1‑for‑10 reverse stock split and announcing Health Canada’s approval of its generic rivaroxaban tablets in four strengths. The move positions the...
Cellular Reprogramming Helps Outsmart Progressive Alzheimers Disease
Researchers at Spain’s Institute for Neurosciences and EPFL have identified an experimental molecule, OLE, that reprograms microglia to better contain β‑amyloid plaques. In mouse models, three months of OLE treatment reduced plaque size and restored memory performance, while worm models...
ASCO26: AZ Triplet Makes Waves in Frontline Liver Cancer
AstraZeneca’s three‑drug combo of Imfinzi, Imjudo and Lenvima, added to transarterial chemoembolisation (TACE), cut the risk of disease progression or death by 30 % in unresectable hepatocellular carcinoma. In the EMERALD‑3 trial the triplet extended median progression‑free survival (PFS) to 13 months...
Amgen Reports the EC Approval of Imdylltra to Treat ES-SCLC
Amgen’s bispecific antibody Imdylltra (tarlatamab) received European Commission approval for treating adults with extensive‑stage small cell lung cancer (ES‑SCLC) who have progressed after platinum‑based first‑line therapy. The decision follows the Phase III DELPHI‑304 trial, which enrolled 509 patients and compared Imdylltra...
Crémieux: Viagra for Life Extension Does It Work? I'm Doubtful
Recent Mendelian‑randomisation studies examined whether phosphodiesterase‑5 (PDE5) inhibitors such as Viagra affect dementia risk. One 2025 analysis linked genetically proxied PDE5 inhibition to modestly higher odds of Alzheimer’s disease (OR 1.09) and a pronounced increase in Lewy‑body dementia (OR 1.32), while a...
New Magnetic Particle Imaging Ensures Precision Cell Therapy Injection Tracking
Scientists at Johns Hopkins Medicine demonstrated that magnetic particle imaging (MPI) can track therapeutic cells in live mice, revealing real‑time distribution after injection. The NIH‑funded study, published May 6, 2026 in Science Advances, compared arterial and venous delivery of mesenchymal stem cells...
A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs
VeriSIM Life has introduced a credit‑score‑like risk assessment tool within its BIOiSIM platform that predicts clinical trial success with roughly 90 % accuracy. The system blends mechanistic animal‑to‑human simulations with machine‑learning models, generating synthetic data to overcome limited experimental inputs. Around...
CRISPR Gene Editing Reveals Role of Collagen Dysfunction in Cerebral Microbleeds
Researchers at Ajou University used CRISPR/Cas9 delivered by the AAV‑BR1 viral vector to delete the Col4a1 gene in adult mouse brain microvascular endothelial cells, creating a scalable model that produces cerebral microbleeds mirroring human MRI lesions. The model allows dose‑dependent...
Akeso’s Ivonescimab Meets Next Phase III Lung Cancer Goal, as Competitors Line Up
Akeso Therapeutics announced that its bispecific antibody ivonescimab met the primary overall‑survival endpoint in a Phase III trial for advanced non‑small cell lung cancer (NSCLC). The study showed a statistically significant survival benefit versus standard chemotherapy, with a manageable safety profile...
ATS 2026: Insmed Shines in Bronchiectasis with Spotlight on Brinsupri
Insmed used the 2026 American Thoracic Society meeting to showcase Brinsupri, its first‑to‑market DPP‑1 inhibitor for non‑cystic fibrosis bronchiectasis. The company presented post‑hoc Phase III ASPEN data indicating dose‑dependent improvements in patient‑reported respiratory symptoms and released a survey highlighting the disease’s...
Scientists Race to Test Bundibugyo Virus Vaccine Candidates
Scientists are scrambling to test vaccines and drugs that can work against the Bundibugyo virus. Here's my story on some of their prime candidates. Gift link: https://nyti.ms/4u7cN4A
WGS Uncovers Clinically Relevant Findings Missed in MDS
Whole genome sequencing [WGS] to identify novel, clinically relevant findings missed by standard of care for Pts w/ myelodysplastic syndrome [MDS] - @AlexBataller et al @garciamanero @UTMDAnderson @TempusAI #ASCO26 abst 6570 Pst 363 https://t.co/t7aNW89eRL #MDSsm #leusm #cagenome
Zaynich's Blockbuster Potential Lifts Wockhardt's Long-Term Outlook
Wockhardt secured USFDA approval for its novel antibiotic Zaynich, marking the first Indian‑developed new chemical entity to clear the regulator after a 12‑year effort. The drug targets multidrug‑resistant gram‑negative urinary‑tract infections and is expected to generate peak sales of $1.5 billion...
Cogent Biosciences' Bezuclastinib‑Sunitinib Combo Doubles PFS in GIST Trial
Cogent Biosciences announced Phase 3 PEAK trial results showing its bezuclastinib‑sunitinib combination doubled median progression‑free survival to 16.5 months versus 9.2 months with sunitinib alone in gastrointestinal stromal tumor patients. The data, presented at the 2026 ASCO meeting, represent the first statistically significant...
Is an Emerging Pharmacotherapeutic Era for Rare Mitochondrial Diseases Here?
After decades of therapeutic void, mitochondrial disease care is entering a new pharmacologic era. In the past year the FDA approved elamipretide (Forzinity) for Barth syndrome and deoxynucleoside therapy (Kygevvi) for TK2 deficiency, marking the first disease‑specific drugs for these...
Biologics Sustain Psoriasis Control at Half Dose
For people with stable psoriasis, newer biologics often maintained symptom control at two-thirds or even half the standard dose. The taper was gradual and supervised, with some able to go much longer between injections. psoriasis
RNA 'Cut-and-Patch' Tool Repairs Faulty Messages without Altering DNA
University of Hong Kong researchers unveiled RNA Segment Editing (RSE), a "cut‑and‑patch" platform that precisely removes and replaces faulty RNA segments in living cells without altering DNA. The tool leverages an engineered Cas13 enzyme to achieve segment‑level editing, a capability...
Living Brain Gene Activity Revealed Noninvasively Through Programmable Blood Test
Rice University bioengineers have unveiled INTACT, a programmable blood‑based assay that captures real‑time transcription of selected genes in living brain tissue. The platform couples engineered Released Markers of Activity (RMAs) with mRNA‑sensing sensors, releasing detectable markers into the bloodstream. In...
GRAIL’s PATHFINDER 2 Shows Galleri Test Boosts Cancer Detection 6.5‑Fold at ASCO 2026
GRAIL announced at the 2026 ASCO meeting that its Galleri multi‑cancer early detection test increased cancer detection 6.5‑fold when combined with standard screenings in a 35,878‑person PATHFINDER 2 trial, with 71% of newly found cancers diagnosed at stages I‑III. The results reinforce...
Waypoint Bio Raises $20M Series A
Waypoint Bio, an AI‑native biotech based in New York, closed a $20 million Series A round led by Amplify Partners. The financing brings new board member Elliot Hershberg and adds General Catalyst, Time BioVentures, Mitsui Global Investments, and Lux Capital among others. The...
Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives
Crystalys Therapeutics dosed the first patient in its Phase II AMETHYST trial of dotinurad, a once‑daily URAT1 inhibitor designed for gout patients who cannot tolerate xanthine oxidase inhibitors. The company estimates a U.S. second‑line market of 500,000‑600,000 patients, roughly 10% of...
ASCO26 Highlights Bispecifics, ADCs, RAS Revolution, Prostate Breakthrough
New, from #ASCO26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer https://t.co/rJehfuYEK0 @ByJonGardner and @Lilah_Alvarado $RVMD $MRK $SMMT $JNJ
Idvynso, Merck’s Once-Daily HIV Pill, Wins FDA Approval
The FDA has granted approval to Merck’s Idvynso, a once‑daily fixed‑dose tablet combining doravirine and islatravir, for adults with HIV‑1 who are already virologically suppressed. The drug offers a two‑drug, tenofovir‑free regimen and is the first non‑INSTI option to demonstrate...
Biotech IPO Market Strengthens in 2026, but Quality Bar Remains High
Cooley partners Charlie Kim and Div Gupta told BioXconomy that biotech IPO activity is picking up in 2026, with a noticeable rise in deal volume and higher median valuations. They highlighted that investors are still demanding rigorous data packages and...
Turning the Patent Cliff Into a Bioplant Opportunity
The looming 2030 patent cliff threatens roughly $300 billion in biopharma revenue as 200 drugs lose exclusivity. Phylloceuticals proposes a duckweed‑based (Lemna) expression system that can slash upstream production costs by up to 90% and cut overall expenses by two‑thirds. The...
Smart Drug that Strips Cancer Cells of ‘Invisibility Cloak’ Can Shrink Tumours by 30%, Trial Shows
Researchers at Oxford’s Greywolf Therapeutics reported that the oral drug GRWD5769, when paired with cemiplimab immunotherapy, caused tumor shrinkage in 26 of 83 heavily pre‑treated patients across six common cancer types. Fifteen of those patients saw reductions of at least...
Pharma’s Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset
Clinical trials now absorb 60‑70% of pharma R&D spend, yet they still run on legacy, site‑centric systems designed for paper workflows. This mismatch creates invisible waste, fragmented data flows, and escalating costs, limiting the impact of emerging AI tools. The...
Creatine Supplementation Cuts Early Alzheimer’s Decline by 30% in New Study
Researchers at the University of Kansas Medical Center found that daily creatine supplementation increased brain phosphocreatine levels and slowed cognitive decline in early Alzheimer’s patients by roughly 30%. The findings, based on a 240‑patient trial, suggest a cheap, widely available...
Novartis Boosts Radioligand Therapy with Pluvicto Success and Actinium-225 Early Data
Novartis unveiled Phase 3 subgroup results showing Pluvicto cuts radiographic progression or death by 28% in metastatic hormone‑sensitive prostate cancer, while early data from its actinium‑225 radioligand demonstrated PSA halving in over half of patients previously treated with Pluvicto. The findings,...
Servier Reports 44‑month Median PFS for VORANIGO in IDH‑mutant Glioma at ASCO
Servier presented extended Phase 3 INDIGO results at the 2026 ASCO meeting, showing a median progression‑free survival of 44.1 months for VORANIGO in grade 2 IDH‑mutant glioma. The data, based on over three years of follow‑up, also highlighted a 72% seizure‑rate reduction and...
Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension
Corsair Pharma announced that its TRX‑248 transdermal patch achieved positive results in a first‑in‑human Phase 1 trial for pulmonary arterial hypertension. The once‑daily patch delivered steady, therapeutically relevant treprostinil plasma levels over 24 hours with pharmacokinetics comparable to subcutaneous delivery and demonstrated...
PF-06826647
Ropsacitinib (PF‑06826647) is an oral TYK2 kinase‑domain inhibitor that progressed to Phase 2b trials for plaque psoriasis and hidradenitis suppurativa. Unlike the approved TYK2 drug deucravacitinib, which binds the JH2 pseudokinase domain, ropsacitinib engages the active JH1 kinase domain, offering a...
ASCO26: Platinum-Resistant ADC Leader Elahere Stumbles in Platinum-Sensitive Disease
AbbVie’s Elahere, the only FDA‑approved FRα‑targeted ADC for platinum‑resistant ovarian cancer, failed to meet its primary endpoint in the Phase II MIROVA trial for platinum‑sensitive disease. The combination of Elahere with carboplatin produced a 66.2% overall response rate but showed no...
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy From Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
Turn Therapeutics released interim data from the first 50 participants in its Phase 2 GX‑03 trial for moderate‑to‑severe atopic dermatitis. By week 4, 92.6% of patients receiving the topical polyhexanide formulation achieved at least a 50% reduction in eczema severity (EASI‑50), compared...
ASCO: Immatics Posts Data on PRAME Pipeline Ahead of Pivotal Readout
Immatics used the ASCO meeting to unveil data on its PRAME‑targeted cell therapies, highlighting early results from next‑generation candidate IMA203CD8 and its lead product anzu‑cel. In a Phase I study, IMA203CD8 induced responses in 12 of 19 gynecologic cancer patients, including...